Migita Toshiro, Ueda Ayano, Ohishi Tomokazu, Hatano Megumi, Seimiya Hiroyuki, Horiguchi Shin-Ichiro, Koga Fumitaka, Shibasaki Futoshi
Department of Molecular Medical Research, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
Lab Invest. 2017 May;97(5):567-576. doi: 10.1038/labinvest.2017.17. Epub 2017 Feb 27.
Bladder cancer is the most common malignant tumor of the urothelium and is classified into non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). Stemness markers such as SOX2 and NANOG are frequently overexpressed in various aggressive cancers, including MIBC; epithelial-mesenchymal transition (EMT) has been proposed as a potential trigger of stemness in cancers. To determine whether cancer stemness is acquired via EMT in bladder cancer, we studied the effect of EMT on the expression of SOX2 and NANOG in bladder cancer cell lines. We also analyzed their expression in clinical tissue samples. Our results revealed that a potent EMT inducer (transforming growth factor β1) reduced the expression of the epithelial marker E-cadherin and increased expression of both SOX2 and NANOG in epithelial-type bladder cancer cells. As for clinical bladder cancer samples, in NMIBC, E-cadherin expression was slightly diminished, and the expression of both SOX2 and NANOG was negligible. In contrast, in MIBC, E-cadherin expression was highly and heterogeneously diminished, while the expression of both SOX2 and NANOG was increased. We also noticed that either E-cadherin or SOX2 (or NANOG) was expressed (ie, in a manner exclusive of each other). In addition, the concentration of E-cadherin showed a significant negative correlation with tumor grade and stage, while expression of SOX2 and NANOG positively correlated with those clinicopathological parameters. These findings suggest that EMT promotes stemness of bladder cancer cells, contributing to tumor aggressiveness. This EMT-cancer stemness axis may also play an important role in the pathogenesis of NMIBC and MIBC.Laboratory Investigation advance online publication, 27 February 2017; doi:10.1038/labinvest.2017.17.
膀胱癌是最常见的尿路上皮恶性肿瘤,分为非肌层浸润性膀胱癌(NMIBC)和肌层浸润性膀胱癌(MIBC)。SOX2和NANOG等干性标志物在包括MIBC在内的各种侵袭性癌症中经常过度表达;上皮-间质转化(EMT)被认为是癌症干性的潜在触发因素。为了确定膀胱癌的癌症干性是否通过EMT获得,我们研究了EMT对膀胱癌细胞系中SOX2和NANOG表达的影响。我们还分析了它们在临床组织样本中的表达。我们的结果显示,一种有效的EMT诱导剂(转化生长因子β1)降低了上皮型膀胱癌细胞中上皮标志物E-钙黏蛋白的表达,并增加了SOX2和NANOG的表达。至于临床膀胱癌样本,在NMIBC中,E-钙黏蛋白表达略有减少,而SOX2和NANOG的表达可忽略不计。相反,在MIBC中,E-钙黏蛋白表达高度且异质性降低,而SOX2和NANOG的表达增加。我们还注意到E-钙黏蛋白或SOX2(或NANOG)呈互斥性表达。此外,E-钙黏蛋白的浓度与肿瘤分级和分期呈显著负相关,而SOX2和NANOG的表达与这些临床病理参数呈正相关。这些发现表明,EMT促进膀胱癌细胞的干性,导致肿瘤侵袭性。这种EMT-癌症干性轴可能在NMIBC和MIBC的发病机制中也起重要作用。《实验室研究》在线优先发表,2017年2月27日;doi:10.1038/labinvest.2017.17